The 52-week high and low prices can offer valuable insights into a stock’s current standing and prospects for future performance. Virax Biolabs Group Ltd’s current trading price is -69.22% away from its 52-week high, while its distance from the 52-week low is 361.77%. The stock’s price range for this period has been between $0.60 and $9.00 The company’s shares, which are part of the Healthcare sector, had a trading volume of approximately 76.44 million for the day, a number notably higher than the average daily volume of 4.57 million over the last three months.
The market performance of Virax Biolabs Group Ltd’s stock has been harmonious in recent times. Over the last year, the company’s stock reached its highest point at $9.00 on 08/19/24, while the lowest value for the same duration was $0.60 on 05/03/24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
Virax Biolabs Group Ltd (VRAX) has experienced a quarterly rise of 136.80% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 12.02M and boasts a workforce of 17 employees.
Analyzing Trading Volume and Moving Average Trends
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.0628, with a change in price of +1.5501. Similarly, Virax Biolabs Group Ltd recorded 4,624,598 in trading volume during the last 100 days, posting a change of +131.36%.
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for VRAX stands at 0.04. Similarly, the long-term debt-to-equity ratio is also 0.03.
VRAX Stock Stochastic Average
As of today, Virax Biolabs Group Ltd’s raw stochastic average for the last 50 days stands at 19.82%. This is a decline compared to the raw stochastic average of the previous 20 days, which was noted at 58.80%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 37.12% and 22.91%, respectively.
VRAX Stock Price Performance Analysis
A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. Year to date metric has recorded a gain of 89.77%.However, over the last six months, we can see a weaker performance of 317.51%. Over the last 30 days, the price of VRAX has fallen by 43.55%. And in the last five days, it has surged by 72.09%.
